Pharmaceutical

Pfizer's Viagra patent partially rejected in Lilly fight

February 16, 2010
Bloomberg News
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn't different enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against Eli Lilly and Co. over its rival Cialis drug.
More

Mississippi settles Zyprexa suit against Lilly for over $18M

February 4, 2010
Associated Press
Mississippi will receive $18.5 million from Indianapolis-based drugmaker Eli Lilly and Co. as part of a settlement over claims the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat.
More

Enzon Pharmaceuticals sells Indy drug plant; 100 local jobs safe

February 1, 2010
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
More

City of Greenwood might fund launch of insulin makerRestricted Content

January 30, 2010
Kathleen McLaughlin
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin, a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
More

Lilly shares trade down after fourth-quarter profits falls

January 28, 2010
J.K. Wall
Analysts worry about dive in already paltry sales of new blood thinner Effient
More

Express Scripts to add 182 pharmacy jobs by 2012

January 27, 2010
 IBJ Staff
Drug distribution firm that acquired former WellPoint subsidiary plans to consolidate specialty pharmacy work at local airport facility.
More

Lilly looks to autoimmune drugs

January 27, 2010
J.K. Wall
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune diseases: The costs of treating them are growing twice as fast as the prescription drug market.
More

Two companies set to make major local expansions

January 27, 2010
Express Scripts Inc. on the west side of Indianapolis and Zipp Speed Weaponry in Speedway are scheduled Wednesday afternoon to announce the creation of hundreds of new jobs.
More

Lilly shares get boost from OK of rival's drug

January 26, 2010
 IBJ Staff and Bloomberg News
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators' clearance of a similar drug.
More

Biotech firm plans $28M Greenwood plant

January 19, 2010
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to help develop a cheaper form of insulin that could gain significant market share.
More

FDA letters scold Lilly, others over marketing materials

January 13, 2010
Associated Press
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately display information about the drug's side effects.
More

Roche taps new local CEO

January 12, 2010
J.K. Wall
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
More

FDA cancels meeting to review Lilly's Cymbalta

January 5, 2010
Associated Press
The agency said the meeting was canceled "to allow time for the FDA to review new information" about a proposed new use for the drug.
More

To keep sales force busy, Lilly takes on new drug

December 24, 2009
J.K. Wall
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel to push.
More

Lilly pays $90 million for autoimmune drug

December 21, 2009
 IBJ Staff
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune diseases.
More

Senate rejects drug-importation proposal

December 16, 2009
 IBJ Staff and Associated Press
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers such as Indianapolis-based Eli Lilly and Co. a victory.
More

Lilly wins approval for long-acting Zyprexa

December 14, 2009
J.K. Wall
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
More

Plainfield's MD Logistics sued by Bristol-Myers over lost insulinRestricted Content

December 12, 2009
Chris O'Malley
Two semi-trailers of the medication were stolen in 2007 from a back lot at Daum Trucking, which isn't named in the lawsuit. Bristol-Myers charges MD Logistics with negligence in the $10.7 million suit.
More

Eli Lilly's shares slip after it forecasts mixed profits in coming years

December 10, 2009
 IBJ Staff and Associated Press
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results could fall precipitously.
More

Lilly launching new venture capital fund

December 10, 2009
J.K. Wall
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's drug pipeline.
More

Ariad asks court to restore patent-suit win against Lilly

December 8, 2009
 IBJ Staff
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent claim.
More

Builder looks to cold storage for steady work in a weak economyRestricted Content

December 5, 2009
Brock Benefiel
Cold storage might become a hot business for a building contractor.
More

Part of Mississippi's Zyprexa case against Lilly dismissed

December 2, 2009
 IBJ Staff
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges improper marketing of antipsychotic drug Zyprexa for unapproved uses.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly's Cymbalta wins new approval for anxiety disorder

November 30, 2009
J.K. Wall
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
More
Page  << 11 12 13 14 15 16 17 18 19 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT